A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.

Trial Details

NCT ID

NCT06679036

Phase

PHASE1 / PHASE2

Sponsor

Shandong Suncadia Medicine Co., Ltd.

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

HRS-2189
Fluvustat
HRS-8080
HRS-6209
HRS-1358

Locations (sample)

Harbin, Heilongjiang, China|45.75,126.65
Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

ECOG physical condition 0-1 point.
Advanced unresectable or metastatic breast cancer confirmed by histopathology or cytopathology.
Menopausal Status.
Previous treatments: (New) adjuvant endocrine therapy combined or not combined with CDK4/6 inhibitors during or within 12 months after treatment, i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →